Biotech firm Dyne Therapeutics is set to host an investor conference call and webcast on June 17. The company recently received breakthrough status for its treatment DYNE-101 for myotonic dystrophy, a genetic disorder affecting muscle function.
In other news, Oppenheimer has adjusted the price target for Dyne Therapeutics to $34 from $60, maintaining an outperform rating. RBC has also cut its price target to $30 from $36, while keeping an outperform and speculative risk rating.
Dyne Therapeutics reported a wider Q1 loss in May, with shares rising despite the news. The company has received orphan drug status for a Duchenne muscular dystrophy treatment and recently announced management changes.
Additionally, Dyne Therapeutics has obtained European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251, which is being developed to treat Duchenne muscular dystrophy. The company’s CFO, Erick Lucera, was named in March, and Dyne Therapeutics plans to present data from its ongoing DELIVER clinical trial at the 2025 MDA Clinical & Scientific Conference.
The US FDA has also granted fast-track status for a neuromuscular disease therapy, further supporting Dyne Therapeutics’ pipeline. With several updates and developments in recent weeks, investors will be eager to hear more about the company’s progress during the investor conference call and webcast.
Source: https://www.marketscreener.com/quote/stock/DYNE-THERAPEUTICS-INC-112544281/news/Dyne-Therapeutics-To-Host-Investor-Conference-Call-And-Webcast-50255006